[{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"FB102","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Ovoca Bio","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"BP-101","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forte Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"Forte Biosciences \/ Ovoca Bio","highestDevelopmentStatusID":"10","companyTruncated":"Forte Biosciences \/ Ovoca Bio"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Public Offering","leadProduct":"FB-102","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ TD Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ TD Cowen"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Forte Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Merger","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Tocagen","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Tocagen"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Forte Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Microorganism","year":"2020","type":"Merger","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Forte Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Forte Biosciences \/ Forte Biosciences"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"FB-102","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ OrbiMed Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Toca 511","moa":"HSV-tk gene","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Alger","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"FB-102","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Forte Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Alger","highestDevelopmentStatusID":"4","companyTruncated":"Forte Biosciences \/ Alger"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Vocimagene Amiretrorepvec","moa":"CDA","graph1":"Oncology","graph2":"Discovery","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Denovo Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Forte Biosciences \/ Denovo Biopharma"}]

Find Clinical Drug Pipeline Developments & Deals by Forte Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : The proceeds from the offering will be used to fund the clinical development of FB-102, which is being evaluated for the treatment of celiac disease.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          June 25, 2025

                          Lead Product(s) : FB-102

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : TD Cowen

                          Deal Size : $75.0 million

                          Deal Type : Public Offering

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 02, 2025

                          Lead Product(s) : FB102

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : The proceeds will support the clinical advancement of FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          November 20, 2024

                          Lead Product(s) : FB-102

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Sponsor : OrbiMed Advisors

                          Deal Size : $53.0 million

                          Deal Type : Private Placement

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : The net financing will support the advancement of FB-102, which targets CD-122 and has demonstrated potentially best in class activity in graft versus host disease (GvHD).

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          January 08, 2023

                          Lead Product(s) : FB-102

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Alger

                          Deal Size : $25.0 million

                          Deal Type : Financing

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          June 23, 2021

                          Lead Product(s) : FB-401

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measu...

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          February 09, 2021

                          Lead Product(s) : FB-401

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : The primary endpoint of EASI-50 was achieved by 58% of subjects on FB-401 compared to 60% of subjects on placebo. Positive trends were observed in key secondary endpoints including EASI-90 with 27.6% of subjects in the active arm achieving the EASI-90 en...

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          February 09, 2021

                          Lead Product(s) : FB-401

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : FB-401 is a topically applied live biotherapeutic consisting of specifically selected strains of commensal Roseomonas mucosa and has demonstrated excellent tolerability and significant improvement in atopic dermatitis disease activity in both adults and ...

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          October 26, 2020

                          Lead Product(s) : FB-401

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : The multi-center, placebo controlled clinical trial of FB-401 is expected to enroll approximately 124 pediatric, adolescent and adult subjects aged 2 years of age and older with atopic dermatitis (AD).

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          September 29, 2020

                          Lead Product(s) : FB-401

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          August 07, 2020

                          Lead Product(s) : FB-401

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank